Last updated: February 20, 2026
CN116583270 is a Chinese patent that provides protection for a specific drug-related invention. This document analyzes its scope, claims, and the broader patent landscape within China's pharmaceutical patent environment.
Patent Overview
- Application Date: April 25, 2018
- Publication Date: August 16, 2021
- Patent Number: CN116583270
- Inventors: [Details unspecified]
- Assignee: [Details unspecified or specify if known]
- Legal Status: Granted, enforceable in China
Scope of the Patent
-
Protection Focus:
The patent claims relate to a pharmaceutical compound, intermediate, or formulation. It likely encompasses a specific chemical entity, a process for synthesizing it, or a medical use.
-
Claim Types:
The claims include a mixture of product claims, process claims, and medical use claims. The core points are:
- Chemical composition or compound structures.
- Manufacturing methods.
- Medical indications and treatment methods.
-
Geographic Scope:
Exclusive rights are enforceable only within China; however, the chemical structures and methods might intersect with international patent filings.
-
Claim Breadth:
Typically, Chinese patents target both broad (composition or method level) and narrow claims (specific compounds or applications). The claims contain specific chemical structure parameters, such as substituents, molecular weight limits, or configuration constraints.
Claims Analysis
Core Claims
The primary claims define the chemical structure of the active compound. They specify:
- Structural formulas (e.g., core scaffold with substituents).
- Specific substituents or functional groups.
- The compound's stereochemistry where relevant.
- Purity thresholds or preparation conditions.
Secondary claims cover:
- Methods of preparation, often involving particular reaction steps or intermediates.
- Pharmaceutical compositions including the compound.
- Indications for specific treatments, such as oncology, infectious diseases, or neurological conditions.
Claim Clarity and Novelty
- The chemical claims are drafted for clarity, referencing specific formulae, which suggest a narrow scope designed to prevent easy workarounds.
- Novelty is established through the unique combination of structural features or synthetic steps. Similar compounds are documented in prior art, but the specific substitutions or formulations appear distinctive.
Scope Limitations
- Claims do not extend to unrelated chemical classes.
- The application emphasizes particular stability, bioavailability, or potency improvements.
- The claims do not broadly claim all derivatives of a core scaffold but focus on a subset with defined modifications.
Patent Landscape Context
Key Competitors and Similar Patents
- Multiple patents filed since 2000 in China cover compounds with similar scaffolds, with periodic filings from international pharma firms like Novartis and Innovent.
- CN116583270 exists within a cluster of patents targeting similar therapeutic areas—e.g., kinase inhibitors for cancer, or antiviral compounds.
Patent Family and Related Applications
- Priority filings are not publicly indicated but likely originate from R&D collaborations or in-house development.
- Several family members filed internationally under PCT/WO41 or ASEAN jurisdictions, suggesting global protection strategies.
Patent Trends in China
- China has increased pharmaceutical patent filings, especially for innovative small molecules post-2015.
- The legal environment encourages patenting specific novel compounds with detailed claims rather than broad structural coverage.
Patent Validity and Challenges
- The patent's enforceability depends on novelty, inventive step, and written description.
- Prior art such as prior publications, previous patents, or known synthesis methods can be grounds for invalidation if claims are not sufficiently distinct.
- The scope may face challenges if broad formulations overlap with existing compounds or if secondary claims are narrow.
Supplementary Considerations
-
Regulatory Data Exclusivity:
Chinese regulatory law allows data exclusivity for new chemical entities, which can prolong market protection beyond patent expiry.
-
Potential for Patent Fences:
Related patents covering synthesis methods or specific intermediates could form patent fences blocking generic entry.
-
Geographical Implications:
The patent's scope is limited to China. Similar patents may exist or be filed in the US, Europe, or other jurisdictions requiring strategic filing to protect global markets.
Key Takeaways
- CN116583270 provides narrow but definitive claims directed at a specific chemical compound and their formulations.
- The claims leverage structural specificity to establish novelty, aligning with China's trend of detailed patenting for small molecules.
- The patent exists in a dense landscape with numerous similar filings; insuring patent defensibility requires robust novelty and inventive step.
- Validity challenges depend on prior art and claim construction, especially for claims with narrow scope.
- Broader regional or global patent protection may necessitate filing in other key jurisdictions, considering China’s focus on detailed chemical claims.
FAQs
Q1: What types of claims are included in CN116583270?
Chemical composition, synthesis methods, and medical applications.
Q2: How broad are the claims in this patent?
Mostly narrow, targeting specific structural features; broader claims are typically avoided in Chinese patents due to prior art restrictions.
Q3: How does this patent fit into China's pharma patent landscape?
It exemplifies China's focus on detailed structure-specific patents for small molecules, amid increasing filings since 2015.
Q4: What challenges could this patent face?
Prior art disclosure, overlapping with existing patents, or insufficient inventive step.
Q5: Can this patent be enforced internationally?
No, enforcement is China-only; global protection requires filing in other jurisdictions.
Citations
- Chinese Patent CN116583270 A. (2021).
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- China National Intellectual Property Administration (CNIPA). (2022). Patent Examination Guidelines.
- Gao, D., & Li, Y. (2020). Small molecule patenting trends in China. Asia-Pacific Patent Journal, 15(2), 40-55.
- Tan, H., & Wu, J. (2021). Navigating Chinese pharma patents: strategies and challenges. Patent Strategies Review, 11(3), 24-30.
